Skip to content
Review

Determinants of response to neoadjuvant chemotherapy in breast cancer: Integrated roles of immune pathways, DNA damage response, and cell cycle regulators

Jul 2026 · Molecular Biology Reports · Vol 53 · 0 citations · 87 references
Medicine

TL;DR

Subtype-specific multi-gene models integrating immune, DDR and cell-cycle biomarkers represent a more powerful tool to predict pCR and improve patient stratification before NAC.

View source

Similar papers

Review Open access Sep 2026

Epigenetic Plasticity in Triple-Negative Breast Cancer: Mechanisms of Therapy Resistance, Biomarkers, and Therapeutic Vulnerabilities

Overall, epigenetic plasticity represents both a major driver of TNBC resistance and a therapeutically exploitable vulnerability, provided those future strategies account for tumor heterogeneity, adaptive cell-state transitions, biomarker-guided patient selection, and combination-based treatment design.

A. Alaa, Salma A. B. El-Din, Mohannad A. Farrag et al. · 0 citations
Review Open access Aug 2026

Current and future therapies for triple-negative breast cancer

This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...

Zi-Xun Wang, Xi-Yu Liu, Yu-Xiao Wu et al. · 0 citations
Open access Sep 2026

The dysregulation of a subset of microRNAs in triple-negative breast cancer is associated with poor survival following neoadjuvant chemotherapy

Findings suggest that the downregulation of specific miRNAs in samples from patients with TNBC may serve as a potential biomarker for predicting the response to neoadjuvant chemotherapy.

B. O. P. Gonçalves, B. Siqueira, Fábio Ribeiro Queiroz et al. · 0 citations
Open access Sep 2026

PD-L1 Expression as a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer

Background: Immune checkpoint blockade has changed the treatment of high-risk early-stage triple-negative breast cancer (TNBC), yet the clinical role of programmed death-ligand 1 (PD-L1) expression in the neoadjuvant setting remains unsettled. PD-L1 may identify an immune-enriched tumor microenvironment and therefore c...

Naznin Nahida, Dhruba Tasnim, Israt Jahan Mukta et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.